HEMISPHERX BIOPHARMA INC's gross profit margin for the second quarter of its fiscal year 2014 has significantly increased when compared to the same period a year ago. While net income decreased, sales have remained unchanged. HEMISPHERX BIOPHARMA INC is extremely liquid. Currently, the Quick Ratio is 4.86 which clearly shows the ability to cover any short-term cash needs. HEB managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.
During the same period, stockholders' equity ("net worth") has decreased by 18.74% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY14||Q2 FY13|
|Net Sales ($mil)||0.04||0.04|
|Net Income ($mil)||-4.96||-4.28|
|Balance Sheet||Q2 FY14||Q2 FY13|
|Cash & Equiv. ($mil)||20.21||32.52|
|Total Assets ($mil)||33.55||46.14|
|Total Debt ($mil)||0.04||7.12|
|Profitability||Q2 FY14||Q2 FY13|
|Gross Profit Margin||-13358.33||-12444.44|
|Return on Assets||-51.03||-43.21|
|Return on Equity||-58.3||-55.16|
|Debt||Q2 FY14||Q2 FY13|
|Share Data||Q2 FY14||Q2 FY13|
|Shares outstanding (mil)||189.5||167.23|
|Div / share||0.0||0.0|
|Book value / share||0.16||0.22|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1922507.0||730412.0|
SELL. This stock?s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. To use another comparison, its price-to-book ratio of 1.74 indicates a discount versus the S&P 500 average of 2.73 and a significant discount versus the industry average of 11.58. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. The valuation analysis reveals that, HEMISPHERX BIOPHARMA INC seems to be trading at a premium to investment alternatives within the industry.
|HEB NM||Peers 61.84||HEB NM||Peers 31.03|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
HEB's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
HEB's P/CF is negative making the measure meaningless.
|HEB NM||Peers 26.00||HEB NA||Peers 1.28|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
HEB's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|HEB 1.74||Peers 11.58||HEB 23.08||Peers 36.27|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
HEB is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, HEB is expected to significantly trail its peers on the basis of its earnings growth rate.
|HEB 284.25||Peers 155.38||HEB 8.23||Peers 139.02|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
HEB is trading at a significant premium to its industry.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
HEB significantly trails its peers on the basis of sales growth
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV